These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

71 related articles for article (PubMed ID: 9188048)

  • 1. Size and conformational stability of the hepatitis A virus used to prepare VAQTA, a highly purified inactivated vaccine.
    Volkin DB; Burke CJ; Marfia KE; Oswald CB; Wolanski B; Middaugh CR
    J Pharm Sci; 1997 Jun; 86(6):666-73. PubMed ID: 9188048
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Optimization of poly(ethylene glycol) precipitation of hepatitis A virus used to prepare VAQTA, a highly purified inactivated vaccine.
    Hagen AJ; Oliver CN; Sitrin RD
    Biotechnol Prog; 1996; 12(3):406-12. PubMed ID: 8652125
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Vaccination against hepatitis A].
    Balli F; Di Biase AR; Viola L
    Pediatr Med Chir; 1996; 18(3):259-62. PubMed ID: 8966125
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of the purity of a purified, inactivated hepatitis A vaccine (VAQTA).
    Hennessey JP; Oswald CB; Dong Z; Lewis JA; Sitrin RD
    Vaccine; 1999 Jul; 17(22):2830-5. PubMed ID: 10438053
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of pH and ionic strength on the physical stability of adenovirus type 5.
    Rexroad J; Evans RK; Middaugh CR
    J Pharm Sci; 2006 Feb; 95(2):237-47. PubMed ID: 16372304
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Supplementary statement on hepatitis A prevention.
    Can Commun Dis Rep; 1996 Jan; 22(1):1-3. PubMed ID: 8825660
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Development of the formalin-inactivated hepatitis A vaccine, VAQTA from the live attenuated virus strain CR326F.
    Armstrong ME; Giesa PA; Davide JP; Redner F; Waterbury JA; Rhoad AE; Keys RD; Provost PJ; Lewis JA
    J Hepatol; 1993; 18 Suppl 2():S20-6. PubMed ID: 8182268
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunopotentiating reconstituted influenza virus virosome vaccine delivery system for immunization against hepatitis A.
    Glück R; Mischler R; Brantschen S; Just M; Althaus B; Cryz SJ
    J Clin Invest; 1992 Dec; 90(6):2491-5. PubMed ID: 1334977
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cell mediated and antibody immune response to inactivated hepatitis A vaccine.
    Schmidtke P; Habermehl P; Knuf M; Meyer CU; Sänger R; Zepp F
    Vaccine; 2005 Oct; 23(44):5127-32. PubMed ID: 16054733
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Properties of a hepatitis A virus candidate vaccine strain.
    Heinricy U; Stierhof YD; Pfisterer M; Flehmig B
    J Gen Virol; 1987 Sep; 68 ( Pt 9)():2487-93. PubMed ID: 2821186
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Establishment of a biological reference preparation for hepatitis A vaccine (inactivated, non-adsorbed).
    Stalder J; Costanzo A; Daas A; Rautmann G; Buchheit KH
    Pharmeur Bio Sci Notes; 2010 Apr; 2010(1):15-29. PubMed ID: 20223187
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Use of nuclease enzyme in the purification of VAQTA, a hepatitis A vaccine.
    Hagen AJ; Aboud RA; DePhillips PA; Oliver CN; Orella CJ; Sitrin RD
    Biotechnol Appl Biochem; 1996 Jun; 23(3):209-15. PubMed ID: 8679106
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Characterization of Inherent Particles and Mechanism of Thermal Stress Induced Particle Formation in HSV-2 Viral Vaccine Candidate.
    Li L; Kirkitadze M; Bhandal K; Roque C; Yang E; Carpick B; Rahman N
    Curr Pharm Biotechnol; 2017 Nov; 18(8):638-647. PubMed ID: 28914197
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A trial of the reactogenicity and immunogenicity of an inactivated hepatitis A vaccine.
    Green MS; Cohen D; Lerman Y; Sjogren M; Binn LN; Zur S; Slepon R; Robin G; Hoke C; Bancroft W
    Isr J Med Sci; 1994; 30(5-6):485-8. PubMed ID: 8034508
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Biophysical validation of Epaxal Berna, a hepatitis A vaccine adjuvanted with immunopotentiating reconstituted influenza virosomes (IRIV).
    Glück R; Wälti E
    Dev Biol (Basel); 2000; 103():189-97. PubMed ID: 11214236
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Epaxal: a virosomal vaccine to prevent hepatitis A infection.
    Bovier PA
    Expert Rev Vaccines; 2008 Oct; 7(8):1141-50. PubMed ID: 18844588
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety and effectiveness of the new inactivated hepatitis A virus vaccine.
    Furesz J; Scheifele DW; Palkonyay L
    CMAJ; 1995 Feb; 152(3):343-8. PubMed ID: 7828098
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Size-exclusion HPLC provides a simple, rapid, and versatile alternative method for quality control of vaccines by characterizing the assembly of antigens.
    Yang Y; Li H; Li Z; Zhang Y; Zhang S; Chen Y; Yu M; Ma G; Su Z
    Vaccine; 2015 Feb; 33(9):1143-50. PubMed ID: 25604799
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Immunogenicity of vaccines against viral hepatitis A and B in the population above 40 years of age -- impact of risk factors].
    Chlíbek R; Smetana J; Sindelár R; Cecetková B; Prymula R; Kohl I
    Epidemiol Mikrobiol Imunol; 2007 Aug; 56(3):119-28. PubMed ID: 17900060
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunogenicity and safety of an inactivated hepatitis A vaccine amongst Singaporeans.
    Guan R; Ng HS; Fock KM; Ho KY; Yap I; Kang JY; Chow WC; Chew CN; Ng C; Teo CJ
    Southeast Asian J Trop Med Public Health; 1995 Jun; 26(2):268-71. PubMed ID: 8629058
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.